NR4A1 and malignant colon neoplasm: Moreover, in a colon cancer model, an NR4A1 antagonist decreased levels of NR4A1, Tox, Tox 2, and NFAT while increasing cytokine production in CD8+ T cells, suggesting that the overexpression of NR4A1 drives T cell exhaustion [22].